Martina Khundakar - Senior Clinical Pharmacist Teresa Barnes - Lead Clinical Pharmacist - Specialist Care. Timothy Donaldson, Trust Chief Pharmacist

Size: px
Start display at page:

Download "Martina Khundakar - Senior Clinical Pharmacist Teresa Barnes - Lead Clinical Pharmacist - Specialist Care. Timothy Donaldson, Trust Chief Pharmacist"

Transcription

1 Policy on Pharmacological Therapies Practice Guidance Note The use of Oral Anti-Cancer Medicines and Oral Methotrexate within - V03 V03 - Issued Issue 1 Dec 15 Planned review December 2018 PPT-PGN 09 Part of NTW(C)38- Pharmacological Therapies Author/Designation Martina Khundakar - Senior Clinical Pharmacist Teresa Barnes - Lead Clinical Pharmacist - Specialist Care Responsible Officer / Designation Timothy Donaldson, Trust Chief Pharmacist Section Contents Page No: 1 Introduction 1 2 Prescribing of Oral Anti-Cancer Medication 2 3 Administration of Oral Anti-Cancer Agents 3 4 Monitoring of Medication Methotrexate Inpatient Treatment of Patients Taking Methotrexate Prescribing of Methotrexate Administration of Oral Methotrexate in Hospitals Symptoms Indicating Possible Toxicity 6 1 Introduction 1.1 The prescribing and administration of oral anti-cancer medicines and oral methotrexate presents a significant risk to patients within Northumberland, Tyne and Wear NHS Foundation Trust (the Trust/NTW). 1.2 Medication which is prescribed at the wrong dose or frequency can result in death or significant morbidity. As a result, it is essential that the prescribing of these medicines takes place under the supervision of an appropriate specialist. 1.3 Treatment with oral anti cancer agents and methotrexate may be necessary for the continuing care of patients with concomitant physical illness, however the prescribing of these agents represents a significant deviation from the expertise and experience of prescribers, pharmacists and nursing staff working within the Trust. 1

2 1.4 The list of oral anticancer medicines currently used can be accessed at: These medicines are prescribed primarily as anticancer agents but may be prescribed for the treatment of other physical illnesses Methotrexate may also be prescribed for the treatment of rheumatoid and psoriatic arthritis, psoriasis and for the treatment of severe Crohn s disease (unlicensed indication). 2 Prescribing of Oral Anti-Cancer Medication 2.1 Treatment with oral anti-cancer medicines and methotrexate must be initiated by an appropriate specialist and not a doctor employed by the Trust. 2.2 Oral anticancer medicines may be prescribed under the direction of a cancer specialist working outside of NTW, provided that they take responsibility for the review of the patient and are able to provide advice to both medical and nursing staff. 2.3 A copy of the patient s treatment plan must be made available to those who are involved in the prescribing, dispensing and administration of oral anticancer agents. 2.4 In the majority of patients, methotrexate is given ONCE WEEKLY ON A SPECIFIED DAY. If prescribed more frequently than this, the prescription (medicine chart) MUST be validated and signed by a clinical pharmacist before being administered to the patient. 2.5 Where patients are to be initiated on an oral anticancer agent within the Trust following steps must be taken to minimise the risks to the patient. The patient should be given the opportunity to ask any relevant questions of the specialist prescribing the medicine or from another specialist familiar with the treatment regime. The patient must have ready access to the Patient Information Leaflet for the prescribed medication. The patient should be aware of the risks associated with treatment and any signs and symptoms that they may need to be aware of during treatment which could be an indication of a problem. The dosage, form and frequency of the medicine must be documented and communicated to the team in writing before any treatment is provided. Where this is not provided this should be requested to prevent unnecessary delay in treatment. Changes in dosage, formulation or frequency must be communicated in writing before these are implemented. Specialists must inform patients directly of any changes to their medication giving opportunity for questions. 2

3 3 Administration of Oral Anti-Cancer Agents 3.1 The pharmacy department will label these medicines with a purple Caution this is a cytostatic or cytotoxic agent sticker to aid recognition of such items. 3.2 Nursing staff must check that all medication is prescribed at the appropriate dosage and frequency before administering to the patient. This should be done by checking the patient s notes for the documented treatment plan. 3.3 Copies of the treatment plan should be made available to the Pharmacy department supplying the medication as an additional safeguard. 3.4 If the patient and medicine are unfamiliar to the nurse administering the medication a secondary check should be made with another colleague who knows the treatment plan and the patient before administration. It should be considered good practice to have a second person check the medicine being administered to the patient 3.5 Nurses involved in the handling of oral anticancer agents must wear appropriate protective clothing in accordance with the instructions provided by the pharmacy department. 3.6 If the dose is anything other than ONCE WEEKLY then the chart MUST have been validated and signed by a clinical pharmacist BEFORE the dose can be given. 4 Monitoring of medication 4.1 Any necessary monitoring of treatment must be stipulated in the treatment plan provided by the specialist. 4.2 The Trust may support the necessary monitoring where possible through regular blood tests as stipulated by the specialist in the treatment plan and assessment of adverse effects. 4.3 Nursing and medical staff must be warned of any additional monitoring that may be necessary during treatment and be aware of signs and symptoms of toxicity. 4.4 These signs/symptoms must be communicated with the named nurse responsible for the patient and all staff involved in his/her care. 4.5 The specialist must be consulted where there are any matters of concern with regard to the patient s treatment and physical health. 3

4 5 Methotrexate 5.1 Overdose of methotrexate for non-cancer treatment is classed as a never event by NHS England. Never Events are serious incidents that are wholly preventable as guidance or safety recommendations that provide strong systemic protective barriers are available at a national level and should have been implemented by all healthcare providers. Each Never Event type has the potential to cause serious patient harm or death. 5.2 The following safe practice checklist has been developed in response to the National Patient Safety Agency (NPSA) alert 03 (2004) updated as alert 13 (2006) Improving compliance with oral methotrexate guidelines issued to prevent incorrect dosing incidents. 5.3 There are many patients being treated with weekly subcutaneous injections of methotrexate for a variety of inflammatory conditions. Although not covered by the National Patient Safety Agency (NPSA) Safety Alert, it has been agreed that the above recommendations should be applied to these patients, as far as they are relevant. 5.4 Inpatient Treatment of Patients Taking Methotrexate The following should have been completed by the specialist prescribing team (e.g. rheumatology, dermatology) at the point of prescribing. It is the responsibility of NTW staff to ensure that patients have been given access to this information. Information on the risks and benefits of oral (and subcutaneous) methotrexate should be given to the patient (or parent/carer) Confirmation that the patient understands and consent should be sought Baseline monitoring tests should be conducted The arrangements for monitoring and the monitoring schedule should be explained to the patient The patient should be issued with a patient held monitoring booklet and information on methotrexate Inpatient staff should ensure that the prescribing, monitoring and administration of oral methotrexate are continued whilst the patient is an inpatient receiving treatment for co-morbid conditions Medicines reconciliation on admission to hospital must be conducted on admission to hospital (Please refer to the Trust s NTW(C)17 - Medicines Policy practice guidance note, UHM-PGN-02 - Prescribing Medicines The prescribing, monitoring and administration requirements for the methotrexate should be recorded in the patient s notes. 4

5 5.5 Prescribing of Methotrexate The prescriber is responsible for recording the correct dosage and frequency on the hospital drug administration chart (Kardex). Days on which a dose is not to be administered must be struck out (see example below) Prescriptions must state the dose of methotrexate and frequency of administration (usually weekly) Handwritten prescriptions and discharge summary information must be complete, legible and include the dosage form and strength. It is hospital trust policy that the only strength of methotrexate tablet used in the hospital is 2.5mg. Letters to GPs and outpatient/discharge prescriptions should clearly indicate the dose in terms of 2.5 mg tablets e.g. a 15 mg dose should be prescribed as Methotrexate 2.5mg tablets, take SIX tablets ONCE Weekly or Methotrexate, SIX 2.5mg tablets ONCE Weekly The results of any patient monitoring and changes in dose must be entered into the patient s hand held record It is hospital trust policy that the only strength of methotrexate tablet used in the hospital is 2.5mg. Letters to GPs and outpatient/discharge prescriptions should clearly indicate the dose in terms of 2.5 mg tablets e.g. a 15 mg dose should be prescribed as Methotrexate 2.5mg tablets, take SIX tablets ONCE Weekly or Methotrexate, SIX 2.5mg tablets ONCE Weekly Ensure details of dose changes recommended by specialists are recorded in the patient s monitoring booklet In the majority of patients, methotrexate is given ONCE WEEKLY ON A SPECIFIED DAY. If prescribed more frequently than this, the prescription (medicine chart) MUST be validated and signed by a clinical pharmacist before being administered to the patient. 5.6 Administration of Oral Methotrexate in Hospitals Follow the guidance detailed within the Trust s NTW(C)17 - Medicines Policy practice guidance note UHM-PGN-03 - Administration of Medicines. 5

6 5.6.2 In addition, ask the patient to confirm the following: That they are still taking methotrexate The dose of the medication How often they take the medicine and when they last took it. For conditions usually seen by this Trust methotrexate should be prescribed once weekly Record the medication given on the prescription/administration chart (Kardex) at the time of administration. A delay in recording administration can result in one or more additional doses being given. If the dose is anything other than ONCE WEEKLY then the chart MUST have been validated and signed by a clinical pharmacist BEFORE the dose can be given. 5.7 Symptoms Indicating Possible Toxicity Patients complaining of the following symptoms and taking methotrexate could have methotrexate toxicity or intolerance: Rash or oral ulceration Nausea and vomiting Diarrhoea Dry, persistent cough Breathlessness Any sign of infection, particularly sore throat Abnormal bruising 6

Improving compliance with oral methotrexate guidelines. Action for the NHS

Improving compliance with oral methotrexate guidelines. Action for the NHS Patient safety alert 13 Alert Immediate action Action Update Information request Ref: NPSA/2006/13 Improving compliance with oral methotrexate guidelines Oral methotrexate is a safe and effective medication

More information

Croydon Health Services NHS Trust (Working in Partnership) Shared Care Guideline: Prescribing Agreement

Croydon Health Services NHS Trust (Working in Partnership) Shared Care Guideline: Prescribing Agreement Shared Care Guideline: Prescribing Agreement Section A: To be completed by the hospital consultant initiating the treatment GP Practice Details: Name: Address: Tel no: Fax no: NHS.net e-mail: Consultant

More information

Pharmacological Therapy Practice Guidance Note Medicine Reconciliation on Admission to Hospital for Adults in all Clinical Areas within NTW V02

Pharmacological Therapy Practice Guidance Note Medicine Reconciliation on Admission to Hospital for Adults in all Clinical Areas within NTW V02 Pharmacological Therapy Practice Guidance Note Medicine Reconciliation on Admission to Hospital for Adults in all Clinical Areas within NTW V02 V02 issued Issue 1 May 11 Issue 2 Dec 11 Planned review May

More information

NPSA Alert 03: Reducing the harm caused by oral Methotrexate. Implementation Progress Report July Learning and Sharing

NPSA Alert 03: Reducing the harm caused by oral Methotrexate. Implementation Progress Report July Learning and Sharing NPSA Alert 03: Reducing the harm caused by oral Methotrexate Implementation Progress Report July 2006 Learning and Sharing CONTENTS Page 1 Background 3 2 Findings 4 Appendix 1 Summary of responses 6 Appendix

More information

ORAL ANTI-CANCER THERAPY POLICY

ORAL ANTI-CANCER THERAPY POLICY ORAL ANTI-CANCER THERAPY POLICY Document Author Written By: Lead Oncology Pharmacist Authorised Authorised By: Chief Executive Officer Date: vember 2016 Date: 11 th April 2017 Lead Director: Executive

More information

SELF - ADMINISTRATION OF MEDICINES AND ADMINISTRATION OF MEDICINES SUPPORTED BY FAMILY/INFORMAL CARERS OF PATIENTS IN COMMUNITY NURSING

SELF - ADMINISTRATION OF MEDICINES AND ADMINISTRATION OF MEDICINES SUPPORTED BY FAMILY/INFORMAL CARERS OF PATIENTS IN COMMUNITY NURSING CLINICAL PROTOCOL SELF - ADMINISTRATION OF MEDICINES AND ADMINISTRATION OF MEDICINES SUPPORTED BY FAMILY/INFORMAL CARERS OF PATIENTS IN COMMUNITY NURSING RATIONALE Medication errors can cause unnecessary

More information

METHOTREXATE TOXICITY

METHOTREXATE TOXICITY METHOTREXATE TOXICITY AN INQUIRY INTO THE DEATH OF A CAMBRIDGESHIRE PATIENT IN APRIL 2000 CAMBRIDGESHIRE HEALTH AUTHORITY JULY 2000 CONTENTS PAGE 1 Introduction 2 2 Background 2 3 Context 2 4 Purpose of

More information

Clinical Check of Prescriptions in Ward Areas

Clinical Check of Prescriptions in Ward Areas Pharmacy Department Standard Operating Procedures SOP Title Clinical Check of Prescriptions in Ward Areas Author name and Gareth Price designation: Deputy Director of Pharmacy Clinical Services Pharmacy

More information

NHS Fife. Patient Group Direction for Named Community Pharmacists to Supply

NHS Fife. Patient Group Direction for Named Community Pharmacists to Supply Patient Group Direction for Named Community Pharmacists to Supply Senna tablets 7.5mg or Senna syrup 7.5mg/5ml (Total sennosides calculated as sennoside B) For patients aged 16 years and older prescribed

More information

Ensuring our safeguarding arrangements act to help and protect adults PRACTICE GUIDANCE FOR REPORTING MEDICATION INCIDENTS INTO SAFEGUARDING

Ensuring our safeguarding arrangements act to help and protect adults PRACTICE GUIDANCE FOR REPORTING MEDICATION INCIDENTS INTO SAFEGUARDING Ensuring our safeguarding arrangements act to help and protect adults PRACTICE GUIDANCE FOR REPORTING MEDICATION INCIDENTS INTO SAFEGUARDING Contents Page 1.0 Purpose 2 2.0 Definition of medication error

More information

POLICY FOR ANTICIPATORY PRESCRIBING FOR PATIENTS WITH A TERMINAL ILLNESS Just in Case

POLICY FOR ANTICIPATORY PRESCRIBING FOR PATIENTS WITH A TERMINAL ILLNESS Just in Case POLICY FOR ANTICIPATORY PRESCRIBING FOR PATIENTS WITH A TERMINAL ILLNESS Just in Case DOCUMENT NO: DN116 Lead author/initiator(s): Sarah Woodley Community Health Services Pharmacist sarah.woodley@ccs.nhs.uk

More information

WHAT are medication errors?

WHAT are medication errors? Healthcare Case Study: Errors Cause Mapping Problem Solving Incident Investigation Root Cause Analysis Errors Angela Griffith, P.E. webinars@thinkreliability.com www.thinkreliability.com Office 281-412-7766

More information

ADMINISTRATION OF MEDICATION BY DELEGATION

ADMINISTRATION OF MEDICATION BY DELEGATION ADMINISTRATION OF MEDICATION BY DELEGATION ROLE AND RESPONSIBILITY OF THE TEACHER TRAINING MANUAL Medication Training Manual Final 10-2-17 Page 1 of 17 MEDICATION ADMINISTRATION TRAINING OBJECTIVES UPON

More information

Primary care attitudes to methotrexate monitoring

Primary care attitudes to methotrexate monitoring Quality in Primary Care 2012;20:443 7 # 2012 Radcliffe Publishing Research paper Primary care attitudes to methotrexate monitoring Rachel Byng-Maddick MBBS BSc MRCP (Rheum) Specialist Registrar in Rheumatology,

More information

Recommendations from National Patient Safety Agency alerts that remain relevant to the Never Events list 2018

Recommendations from National Patient Safety Agency alerts that remain relevant to the Never Events list 2018 Recommendations from National Patient Safety Agency alerts that remain relevant to the Never Events list 2018 January 2018 We support providers to give patients safe, high quality, compassionate care within

More information

PATIENT GROUP DIRECTION (PGD) FOR THE SUPPLY OF DOXYCYCLINE 100MG CAPSULES / TABLETS FOR THE FIRST- LINE TREATMENT OF CHLAMYDIA TRACHOMATIS INFECTION

PATIENT GROUP DIRECTION (PGD) FOR THE SUPPLY OF DOXYCYCLINE 100MG CAPSULES / TABLETS FOR THE FIRST- LINE TREATMENT OF CHLAMYDIA TRACHOMATIS INFECTION This Patient Group Direction () must only be used by registered pharmacists who have been named and authorised by their organisation to practice under it. The most recent and in date final signed version

More information

Oxfordshire Anticoagulation Service. Important information about anticoagulation with vitamin K antagonists Information for patients

Oxfordshire Anticoagulation Service. Important information about anticoagulation with vitamin K antagonists Information for patients Oxfordshire Anticoagulation Service Important information about anticoagulation with vitamin K antagonists Information for patients Page 2 Your information Name:... Address:......... or patient stickie

More information

PROPOSAL TO UPDATE NEAR PATIENT TESTING ENHANCED SERVICE

PROPOSAL TO UPDATE NEAR PATIENT TESTING ENHANCED SERVICE PROPOSAL TO UPDATE NEAR PATIENT TESTING ENHANCED SERVICE 1.0 ACTION BY AWMSG: The All Wales Medicines Strategy Group (AWMSG) meeting held on 15 th December 2010 considered and approved the recommendations

More information

SHARED CARE GUIDELINE: Unlicensed use of Mercaptopurine for the treatment of Inflammatory Bowel Disease.

SHARED CARE GUIDELINE: Unlicensed use of Mercaptopurine for the treatment of Inflammatory Bowel Disease. LINCOLNSHIRE CLINICAL COMMISSIONING GROUPS in association with UNITED LINCOLNSHIRE HOSPITALS TRUST SHARED CARE GUIDELINE: Unlicensed use of Mercaptopurine for the treatment of Inflammatory Bowel Disease.

More information

Care Coordination and Care Programme Approach Practice Guidance Note Learning Disability Admissions Urgent Care Only V02

Care Coordination and Care Programme Approach Practice Guidance Note Learning Disability Admissions Urgent Care Only V02 Care Coordination and Care Programme Approach Practice Guidance Note Learning Disability Admissions Urgent Care Only V02 Date issued Issue 2 Dec 15 Issue 3 Dec 17 Author/Designation Responsible Officer

More information

Safer use of anticoagulants: the NPSA patient safety alert Steve Chaplin MSc, MRPharmS

Safer use of anticoagulants: the NPSA patient safety alert Steve Chaplin MSc, MRPharmS Safer use of anticoagulants: the NPSA patient safety alert Steve Chaplin MSc, MRPharmS Steve Chaplin describes the NPSA s anticoagulant patient safety alert and the measures it recommends for making the

More information

Medicines Reconciliation: Standard Operating Procedure

Medicines Reconciliation: Standard Operating Procedure Clinical Medicines Reconciliation: Standard Operating Procedure Document Control Summary Status: Version: Author/Owner/Title: Approved by: Ratified: Related Trust Strategy and/or Strategic Aims Implementation

More information

Managing medicines in care homes

Managing medicines in care homes Managing medicines in care homes http://www.nice.org.uk/guidance/sc/sc1.jsp Published: 14 March 2014 Contents What is this guideline about and who is it for?... 5 Purpose of this guideline... 5 Audience

More information

Trust Standard for the Assessment and Management of Physical Health Practice Guidance Note Enteral Tube Feeding Overview V01

Trust Standard for the Assessment and Management of Physical Health Practice Guidance Note Enteral Tube Feeding Overview V01 Trust Standard for the Assessment and Management of Physical Health Practice Guidance Note Enteral Tube Feeding Overview V01 Date Issued Planned Review PGN No: Issue 1 Aug 16 Issue 2 Nov 16 Aug 19 AMPH-PGN-02

More information

Social care guideline Published: 14 March 2014 nice.org.uk/guidance/sc1

Social care guideline Published: 14 March 2014 nice.org.uk/guidance/sc1 Managing medicines in care homes Social care guideline Published: 14 March 2014 nice.org.uk/guidance/sc1 NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).

More information

South Staffordshire and Shropshire Healthcare NHS Foundation Trust

South Staffordshire and Shropshire Healthcare NHS Foundation Trust South Staffordshire and Shropshire Healthcare NHS Foundation Trust Document Version Control Document Type and Title: Authorised Document Folder: Policy for Medicines Reconciliation on Admission and on

More information

Unlicensed Medicines Policy Document

Unlicensed Medicines Policy Document Unlicensed Medicines Policy Document Effective: February 2002 (Intranet 2006) Review date: February 2007 A. Introduction In order to ensure that medicines are safe and effective the manufacture and sale

More information

Medicine Management Policy

Medicine Management Policy INDEX Prescribing Page 2 Dispensing Page 3 Safe Administration Page 4 Problems & Errors Page 5 Self Administration Page 7 Safe Storage Page 8 Controlled Drugs Best Practice Procedure Page 9 Controlled

More information

1. Guidance notes. Social care (Adults, England) Knowledge set for medication. What are knowledge sets? Why were knowledge sets commissioned?

1. Guidance notes. Social care (Adults, England) Knowledge set for medication. What are knowledge sets? Why were knowledge sets commissioned? Social care (Adults, England) Knowledge set for medication 1. Guidance notes What are knowledge sets? Part of the sector skills council Skills for Care and Development Knowledge sets are sets of key learning

More information

All Wales Multidisciplinary Medicines Reconciliation Policy

All Wales Multidisciplinary Medicines Reconciliation Policy All Wales Multidisciplinary Medicines Reconciliation Policy June 2017 This document has been prepared by the Quality and Patient Safety Delivery Group of the All Wales Chief Pharmacists Group, with support

More information

PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:

PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: Cetuximab (+/- platinum-based chemotherapy) HOSPITAL NAME/STAMP: PATIENT DETAILS PATIENT S SURNAME/FAMILY NAME: PATIENT S FIRST NAME(S): DATE OF BIRTH:

More information

Azathioprine. Shared Care Agreement for the treatment of Ulcerative colitis and Crohn s disease with Azathioprine, March 2012 Page 1 of 6

Azathioprine. Shared Care Agreement for the treatment of Ulcerative colitis and Crohn s disease with Azathioprine, March 2012 Page 1 of 6 Azathioprine Shared Care Agreement for the treatment of Ulcerative colitis and Crohn s disease with azathioprine, a copy of which must be supplied by the specialist to the GP at commencement, which will

More information

AMPH-PGN-10 (Part of NTW(C)29 Trust Standard for Physical Assessment and Examination Policy

AMPH-PGN-10 (Part of NTW(C)29 Trust Standard for Physical Assessment and Examination Policy AMPH-PGN-10 Practice Guidance Note Intramuscular Injection (IMI) V01 Date Issued Planned Review PGN No: Issue 1 Sep 2017 Sep 2020 AMPH-PGN-10 (Part of NTW(C)29 Trust Standard for Physical Assessment and

More information

Reconciliation of Medicines on Admission to Hospital

Reconciliation of Medicines on Admission to Hospital Reconciliation of Medicines on Admission to Hospital Policy Title State previous title where relevant. State if Policy New or Revised Policy Strand Org, HR, Clinical, H&S, Infection Control, Finance For

More information

PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:

PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: Cetuximab (+/- Chemotherapy) PATIENT DETAILS PATIENT S SURNAME/FAMILY NAME: PATIENT S FIRST NAME(S): DATE OF BIRTH: NHS NUMBER: (or other identifier)

More information

Patient identifier/label: Page 1 of 6 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM CHOP 21 + RITUXIMAB

Patient identifier/label: Page 1 of 6 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM CHOP 21 + RITUXIMAB Patient identifier/label: Page 1 of 6 FORM CHOP 21 + RITUXIMAB Patient s surname/family name Patient s first names Date of birth Hospital Name: Guy s Hospital St. Thomas Hospital King s College Hospital

More information

How to Report Medication Safety Incidents from a GP Practice on the National Reporting and Learning System (NRLS)

How to Report Medication Safety Incidents from a GP Practice on the National Reporting and Learning System (NRLS) pecialist Pharmacy ervice Medicines Use and afety How to Report Medication afety Incidents from a GP Practice on the National Reporting and Learning ystem (NRL) This document provides a quick explanation

More information

Medication Management Policy and Procedures

Medication Management Policy and Procedures POLICY STATEMENT This policy establishes guidelines for ensuring safe and correct management of client medications in accordance with legislative and regulatory requirements and professional practice competency

More information

Completing the NPA online Patient Safety Incident Report form: 2016

Completing the NPA online Patient Safety Incident Report form: 2016 The National Pharmacy Association (NPA) Patient Safety Incident report form can be used within the community pharmacy to log patient safety incidents. The online form should not include any patientidentifiable

More information

LINCOLNSHIRE CLINICAL COMMISSIONING GROUPS in association with UNITED LINCOLNSHIRE HOSPITALS TRUST

LINCOLNSHIRE CLINICAL COMMISSIONING GROUPS in association with UNITED LINCOLNSHIRE HOSPITALS TRUST LINCOLNSHIRE CLINICAL COMMISSIONING GROUPS in association with UNITED LINCOLNSHIRE HOSPITALS TRUST SHARED CARE GUIDELINE: Azathioprine covering use in Dermatology and Gastroenterology All prescribing of

More information

Page 17. Medication Management Policy and Practice Guidelines

Page 17. Medication Management Policy and Practice Guidelines Page 17 APPENDIX A Medication Management Policy and Practice Guidelines Index Scope Definition of medication Principles underpinning safe use of medications Procedure Guidelines Scope 1. Medication packaging

More information

GENERAL MEDICATION PROCEDURES

GENERAL MEDICATION PROCEDURES GENERAL MEDICATION PROCEDURES In situations where services will be provided in the person s own home or with their family, guardian / responsible party, medication storage, ordering and receiving medications

More information

PATIENT AGREEMENT TO SYSTEMIC THERAPY: GENERIC CONSENT FORM. Patient s first names. Date of birth. Job title

PATIENT AGREEMENT TO SYSTEMIC THERAPY: GENERIC CONSENT FORM. Patient s first names. Date of birth. Job title Patient identifier/label: Page 1 of 5 GENERIC CONSENT FORM Patient s surname/family name Patient s first names Date of birth Hospital Name: NHS number (or other identifier) Male Female Special requirements

More information

Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Communication Care Bundle Guide

Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Communication Care Bundle Guide Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Communication Care Bundle Guide The Scottish Patient Safety Programme (SPSP) is a unique national initiative that aims to improve the safety and reliability

More information

Please call the Pharmacy Medicines Unit on or for a copy.

Please call the Pharmacy Medicines Unit on or for a copy. Title: PATIENT GROUP DIRECTION FOR THE SUPPLY OF FLUCONAZOLE 150MG UNDER THE MINOR AILMENT SERVICE Identifier: Across NHS Boards Organisation Wide Directorate Clinical Service Sub Department Area This

More information

New v1.0 Date: Cathy Riley - Director of Pharmacy Policy and Procedures Committee Policy and Procedures Committee

New v1.0 Date: Cathy Riley - Director of Pharmacy Policy and Procedures Committee Policy and Procedures Committee Clinical Pharmacy Services: SOP Document Control Summary Status: Version: Author/Owner/Title: Approved by: Ratified: Related Trust Strategy and/or Strategic Aims Implementation Date: Review Date: Key Words:

More information

The Medicines Policy. Chapter 6: Standards of Practice. MISCELLANEOUS and DISCHARGE

The Medicines Policy. Chapter 6: Standards of Practice. MISCELLANEOUS and DISCHARGE Chapter 6: Standards of Practice MISCELLANEOUS and DISCHARGE V2.1 Date: October 2015 CHAPTER 6 CONTENTS 6.5. Miscellaneous... 3 6.5.1 Patients Moving Between Healthcare Trusts... 3 6.5.1.1 Transfer of

More information

Expiry Date: January 2009 Template Version: Page 1 of 7

Expiry Date: January 2009 Template Version: Page 1 of 7 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT Clinical Condition Indication: Inclusion criteria: Exclusion criteria: Cautions/Need for

More information

Supporting self-administration of medication in the care home setting

Supporting self-administration of medication in the care home setting B143. November 2016 2.0 Community Interest Company Supporting self-administration of medication in the care home setting Care home residents should have the opportunity to make informed decisions about

More information

Managing Medicines Policy

Managing Medicines Policy Managing Medicines Policy General Guidance: Policy for Administration of Medication in Schools and Early Years Settings 1 The Governors and staff of Townville Infants School wish to ensure that pupils

More information

Reducing Medication Errors: National Update

Reducing Medication Errors: National Update Reducing Medication Errors: National Update Ahmed Ameer Medication Safety Officer Ahmed.Ameer@NHS.net Safer Medication Practice & Medical Devices Team 27 th January 2015 Agenda 1. Development of the National

More information

PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:

PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: Lenvatinib PATIENT DETAILS PATIENT S SURNAME/FAMILY NAME: PATIENT S FIRST NAME(S): DATE OF BIRTH: NHS NUMBER: (or other identifier) HOSPITAL NAME/STAMP:

More information

PROTOCOL FOR THE ADMINISTRATION OF SENNA. Formulary and Prescribing Guidelines

PROTOCOL FOR THE ADMINISTRATION OF SENNA. Formulary and Prescribing Guidelines PROTOCOL FOR THE ADMINISTRATION OF SENNA Formulary and Prescribing Guidelines Introduction This protocol allows for the administration of Senna by a registered nurse without a prescription from a doctor

More information

PATIENT GROUP DIRECTION (PGD) FOR

PATIENT GROUP DIRECTION (PGD) FOR Antibiotic Oral (tablet/capsule/suspension) PATIENT GROUP DIRECTION (PGD) FOR YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT Caution: This

More information

MEDICINES RECONCILIATION GUIDELINE Document Reference

MEDICINES RECONCILIATION GUIDELINE Document Reference MEDICINES RECONCILIATION GUIDELINE Document Reference G358 Version Number 1.01 Author/Lead Job Title Jackie Stark Principle Pharmacist Clinical Services Date last reviewed, (this version) 29 November 2012

More information

Oral Ibrutinib (single agent)

Oral Ibrutinib (single agent) Patient identifier/label: Page 1 of 6 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM IBRUTINIB Patient s surname/family name Patient s first names Date of birth Hospital Name: NHS number (or other

More information

PROCESS FOR INITIATING A SYRINGE DRIVER FOR COMMUNITY NURSE PATIENTS OUT OF HOURS

PROCESS FOR INITIATING A SYRINGE DRIVER FOR COMMUNITY NURSE PATIENTS OUT OF HOURS STANDARD OPERATING PROCEDURE PROCESS FOR INITIATING A SYRINGE DRIVER FOR COMMUNITY NURSE PATIENTS OUT OF HOURS Issue History Issue Version one Purpose of Issue/Description of Change To facilitate patients

More information

Administration of Intrathecal Cytotoxic Chemotherapy in NHS Grampian

Administration of Intrathecal Cytotoxic Chemotherapy in NHS Grampian Administration of Intrathecal Cytotoxic Chemotherapy in NHS Grampian Lead Author/Coordinator: Jeff Horn / Sarah Howlett Macmillan Haematology CNS/ Pharmacist Reviewer: Gavin Preston Consultant Haematologist

More information

Medicines Management Strategy

Medicines Management Strategy Medicines Management Strategy 2012 2014 Directorate responsible for the strategy: Medical and Governance Directorate Staff group to whom it applies: All clinical staff and Trust managers Issue date: 30/6/12

More information

This controlled document shall not be copied in part or whole without the express permission of the author or the author s representative.

This controlled document shall not be copied in part or whole without the express permission of the author or the author s representative. This document is also available in large print and other formats and languages, upon request. Please call NHS Grampian Corporate Communications on (01224) 551116 or (01224) 552245. This controlled document

More information

Policy for Anticipatory Prescribing and Just in Case Bags

Policy for Anticipatory Prescribing and Just in Case Bags Policy for Anticipatory Prescribing and Just in Case Bags This policy was developed by Milton Keynes End of Life Care Medicine Group and has been adopted by all partner organisations (MK Clinical Commissioning

More information

FOR MEDICINE ADMINISTRATION IN COMMUNITY NURSING

FOR MEDICINE ADMINISTRATION IN COMMUNITY NURSING STANDARD OPERATING PROCEDURE FOR MEDICINE ADMINISTRATION IN COMMUNITY NURSING Issue History Issue Version One Purpose of Issue/Description of Change To promote safe and effective medicine administration

More information

MINNESOTA. Downloaded January 2011

MINNESOTA. Downloaded January 2011 MINNESOTA Downloaded January 2011 4658.1300 MEDICATIONS AND PHARMACY SERVICES; DEFINITIONS. Subpart 1. Controlled substances. "Controlled substances" has the meaning given in Minnesota Statutes, section

More information

PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:

PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: Lomustine PATIENT DETAILS PATIENT S SURNAME/FAMILY NAME: PATIENT S FIRST NAME(S): DATE OF BIRTH: NHS NUMBER: (or other identifier) HOSPITAL NAME/STAMP:

More information

Best Practice Guidance for GP Practices, Community Pharmacists and Care Home Providers

Best Practice Guidance for GP Practices, Community Pharmacists and Care Home Providers Medicines Management in Care Homes Best Practice Guidance for GP Practices, Community Pharmacists and Care Home Providers 1. Communication The care home manager, community pharmacist and GP surgery should

More information

MEDICATION MONITORING AND MANAGEMENT Procedures

MEDICATION MONITORING AND MANAGEMENT Procedures MEDICATION MONITORING AND MANAGEMENT Procedures Waiver Programs Purpose To support persons served in their own homes with their medication needs. Scope This procedure applies to all Waiver employees who

More information

Newfoundland and Labrador Pharmacy Board

Newfoundland and Labrador Pharmacy Board Newfoundland and Labrador Pharmacy Board Standards of Practice Prescribing by Pharmacists August 2015 Table of Contents 1) Introduction... 1 2) Requirements... 1 3) Limitations... 1 4) Operational Standards...

More information

Medication Errors in Chemotherapy PORSCHA L. JOHNSON, PHARM.D. CLINICAL PHARMACIST II MEDSTAR WASHINGTON HOSPITAL CENTER SATURDAY, SEPTEMBER 17, 2016

Medication Errors in Chemotherapy PORSCHA L. JOHNSON, PHARM.D. CLINICAL PHARMACIST II MEDSTAR WASHINGTON HOSPITAL CENTER SATURDAY, SEPTEMBER 17, 2016 Medication Errors in Chemotherapy PORSCHA L. JOHNSON, PHARM.D. CLINICAL PHARMACIST II MEDSTAR WASHINGTON HOSPITAL CENTER SATURDAY, SEPTEMBER 17, 2016 DISCLOSURE STATEMENT I have nothing to disclose regarding

More information

PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:

PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: Gemcitabine-Doxorubicin PATIENT DETAILS PATIENT S SURNAME/FAMILY NAME: PATIENT S FIRST NAME(S): DATE OF BIRTH: NHS NUMBER: (or other identifier) HOSPITAL

More information

PATIENT GROUP DIRECTION (PGD) FOR Metronidazole 400mg Tablets

PATIENT GROUP DIRECTION (PGD) FOR Metronidazole 400mg Tablets Antibiotic Oral (tablet/capsule/suspension) PATIENT GROUP DIRECTION (PGD) FOR YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT Caution: This

More information

MMPR034 MEDICINES RECONCILIATION ON ADMISSION TO HOSPITAL PROTOCOL

MMPR034 MEDICINES RECONCILIATION ON ADMISSION TO HOSPITAL PROTOCOL MMPR034 MEDICINES RECONCILIATION ON ADMISSION TO HOSPITAL PROTOCOL 1 Table of Contents Why we need this Protocol...3 What the Protocol is trying to do...3 Which stakeholders have been involved in the creation

More information

PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:

PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: Vinorelbine (oral) PATIENT DETAILS PATIENT S SURNAME/FAMILY NAME: PATIENT S FIRST NAME(S): DATE OF BIRTH: NHS NUMBER: (or other identifier) HOSPITAL

More information

Executive Director of Nursing and Chief Operating Officer

Executive Director of Nursing and Chief Operating Officer Document Title Arrangements for Managing Patients Mental and Physical Health Needs across NTW and the Acute Hospital Trusts Reference Number Lead Officer Author(s) (name and designation) Ratified by NTW(C)15

More information

Methotrexate in General Practice Audit Methotrexate: Using audit to enhance safer use of toxic medication Good for patients, Good for doctors.

Methotrexate in General Practice Audit Methotrexate: Using audit to enhance safer use of toxic medication Good for patients, Good for doctors. Methotrexate in General Practice Audit Methotrexate: Using audit to enhance safer use of toxic medication Good for patients, Good for doctors. AUTHORS Dr. Diarmuid Quinlan Dr. Paul Ryan Purpose of ICGP

More information

Patient identifier/label: Page 1 of 6 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM CYTARABINE CONTINUOUS INFUSION

Patient identifier/label: Page 1 of 6 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM CYTARABINE CONTINUOUS INFUSION Patient identifier/label: Page 1 of 6 CYTARABINE Patient s surname/family name Patient s first names Date of birth Hospital Name: Guy s Hospital St. Thomas Hospital King s College Hospital Lewisham Hospital

More information

The Prescribing, Monitoring and Administration of Depot / Long Acting IM Medication within Community Mental Health Services

The Prescribing, Monitoring and Administration of Depot / Long Acting IM Medication within Community Mental Health Services Standard Operating Procedure 2 (SOP 2) The Prescribing, Monitoring and Administration of Depot / Long Acting IM Medication within Community Mental Health Services Why we have a procedure? Black Country

More information

Patient identifier/label: Page 1 of 6 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM PAZOPANIB. Patient s first names.

Patient identifier/label: Page 1 of 6 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM PAZOPANIB. Patient s first names. Patient identifier/label: Page 1 of 6 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM PAZOPANIB Patient s surname/family name Patient s first names Date of birth Hospital Name: Guy s Hospital St. Thomas

More information

Section 2 Medication Orders

Section 2 Medication Orders Section 2 Medication Orders 2-1 Objectives: 1. List/recognize the components of a complete medication order. 2. Transcribe orders onto the Medication Administration Record (MAR) correctly use proper abbreviations,

More information

Patient identifier/label: Page 1 of 6 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM TRASTUZUMAB (HERCEPTIN) Patient s first names.

Patient identifier/label: Page 1 of 6 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM TRASTUZUMAB (HERCEPTIN) Patient s first names. Patient identifier/label: Page 1 of 6 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM TRASTUZUMAB (HERCEPTIN) Patient s surname/family name Patient s first names Date of birth Hospital Name: NHS number

More information

Section 7: Core clinical headings

Section 7: Core clinical headings Section 7: Core clinical headings Core clinical heading standards: the core clinical headings are those that are the priority for inclusion in EHRs, as they are generally items that are the priority for

More information

Systemic anti-cancer therapy Care Pathway

Systemic anti-cancer therapy Care Pathway Network Guidance Document Status: Expiry Date: Version Number: Publication Date: Final July 2013 V2 July 2011 Page 1 of 9 Contents Contents... 2 STANDARDS FOR PREPARATION AND PHARMACY... 3 1.1 Facilities

More information

Checklists for Preventing and Controlling

Checklists for Preventing and Controlling Checklists for Preventing and Controlling Clostridium difficile Infection (CDI) This document has been developed to specifically assist senior management and all ward staff to take appropriate actions,

More information

Job Title Name Signature Date

Job Title Name Signature Date Supply of Fluconazole 150mg capsule by Community Pharmacists working in Forth Valley Pharmacies under NHS Minor Ailment Service. Protocol Number 125 Version 5 Date protocol prepared: November 2014 Date

More information

SUPPLY BY PHARMACISTS OF A NON-PRESCRIPTION MEDICINAL PRODUCT CONTAINING LEVONORGESTREL (NORLEVO 1.5MG TABLETS) AS EMERGENCY HORMONAL CONTRACEPTION

SUPPLY BY PHARMACISTS OF A NON-PRESCRIPTION MEDICINAL PRODUCT CONTAINING LEVONORGESTREL (NORLEVO 1.5MG TABLETS) AS EMERGENCY HORMONAL CONTRACEPTION SUPPLY BY PHARMACISTS OF A NON-PRESCRIPTION MEDICINAL PRODUCT CONTAINING LEVONORGESTREL (NORLEVO 1.5MG TABLETS) AS EMERGENCY HORMONAL CONTRACEPTION GUIDANCE FOR PHARMACISTS ON SAFE SUPPLY TO PATIENTS (This

More information

Management of Reported Medication Errors Policy

Management of Reported Medication Errors Policy Management of Reported Medication Errors Policy Approved By: Policy & Guideline Committee Date of Original 6 October 2008 Approval: Trust Reference: B45/2008 Version: 4 Supersedes: 3 February 2015 Trust

More information

Physical Health Monitoring Clinic Berwick Patient Information Leaflet

Physical Health Monitoring Clinic Berwick Patient Information Leaflet Physical Health Monitoring Clinic Berwick Patient Information Leaflet Shining a light on the future Introduction This leaflet provides you with information that you will find useful whilst attending the

More information

SAFE Standard of Care

SAFE Standard of Care SAFE Standard of Care THE NEW UK STANDARD OF CARE BANISH MEDICATION ERRORS We all know that when medication is prescribed, dispensed and administered correctly it can dramatically improve the quality of

More information

Electronic Prescribing and emar. Jonathan Sheldon Consultant Physician and Clinical Lead for Electronic patient records

Electronic Prescribing and emar. Jonathan Sheldon Consultant Physician and Clinical Lead for Electronic patient records Electronic Prescribing and emar Jonathan Sheldon Consultant Physician and Clinical Lead for Electronic patient records AIMS To discuss the support needed for the successful conclusion of this project To

More information

Aged residential care (ARC) Medication Chart implementation and training guide (version 1.1)

Aged residential care (ARC) Medication Chart implementation and training guide (version 1.1) Aged residential care (ARC) Medication Chart implementation and training guide (version 1.1) May 2018 Prepared by and the Health Quality & Safety Commission Version 1, March 2018; version 1.1, May 2018

More information

Dr Vincent Kirchner, MEDICAL DIRECTOR. Date Version Summary of amendments Oct New Procedure

Dr Vincent Kirchner, MEDICAL DIRECTOR. Date Version Summary of amendments Oct New Procedure OLANZAPINE DEPOT PROCEDURE OCTOBER 2017 Policy title Policy reference Policy category Relevant to Date published Implementatio n date Date last reviewed Next review date Policy lead Contact details Accountable

More information

Consultation Group: See relevant page in the PGD. Review Date: October 2015

Consultation Group: See relevant page in the PGD. Review Date: October 2015 Patient Group Direction For The Supply Of Trimethoprim For The Treatment Of Women With Uncomplicated Urinary Tract Infections By Nurses And Pharmacists Working Within NHS Grampian Community Pharmacies

More information

Unlicensed Medicines Policy

Unlicensed Medicines Policy Unlicensed Medicines Policy This procedural document supersedes: PAT/MM 4 v.3 Policy and Procedure for the Use of Unlicensed Medicines Did you print this document yourself? The Trust discourages the retention

More information

5. returning the medication container to proper secured storage; and

5. returning the medication container to proper secured storage; and 111-8-63-.20 Medications. (1) Self-Administration of Medications. Residents who have the cognitive and functional capacities to engage in the self-administration of medications safely and independently

More information

Name Job Title Signed Date. This Patient Group Direction is operational from: Oct 2017 Review date: Aug 19. Expires on 31 st October 2019

Name Job Title Signed Date. This Patient Group Direction is operational from: Oct 2017 Review date: Aug 19. Expires on 31 st October 2019 PGD4017 PATIENT GROUP DIRECTION FOR THE SUPPLY OF ACICLOVIR TABLETS FOR THE TREATMENT OF GENITAL HERPES SIMPLEX INFECTIONS by registered nurses and midwives in Integrated Sexual Health services employed

More information

What is TB? Prevention is better than cure. You can get latent or active TB even if you have had a BCG vaccination

What is TB? Prevention is better than cure. You can get latent or active TB even if you have had a BCG vaccination What is TB? Tuberculosis (TB) is an illness caused by bacteria. When someone with TB in their lungs coughs or sneezes, they send TB bacteria into the air. If you breathe in these bacteria, one of three

More information

Template (to be adapted by care home) Medication to be administered on a PRN (when required) basis in a care home environment

Template (to be adapted by care home) Medication to be administered on a PRN (when required) basis in a care home environment Template (to be adapted by care home) Medication to be administered on a PRN (when required) basis in a care home environment The PRN Purpose & Outcome Protocol (PRN POP) Background The term PRN (from

More information